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Abstract 
Constitutional mismatch repair deficiency (CMMRD) is an autosomal recessively inherited childhood 
cancer susceptibility syndrome caused by biallelic germline mutations in one of the mismatch repair (MMR) 
 2 
genes. The spectrum of CMMRD-associated tumours is very broad and many CMMRD patients additionally 
display signposting non-neoplastic features, most frequently café-au-lait macules and other pigmentation 
alterations. 
We report on a 13 months old girl suspected of having CMMRD due to a desmoplastic medulloblastoma 
and a striking skin pigmentation that included multiple café-au-lait macules, hypopigmented areas and 
Mongolian spots. Whole-exome sequencing revealed homozygosity for MSH2 variant p.(Leu92Val) and MSH6 
variant p.(Val809del), both variants of uncertain significance. Immunohistochemical analysis of the tumour 
tissue showed expression of all four MMR proteins and gMSI testing was negative. However, functional assays 
demonstrated that the cells of the patient displayed methylation tolerance and ex vivo microsatellite 
instability, which unequivocally confirmed the diagnosis of CMMRD. Taken together, the results render the 
MSH2 variant. unlikely to be responsible for the phenotype , while they are compatible with MSH6-associated 
CMMRD. 
This case illustrates the diagnostic strategy of confirming CMMRD syndrome in patients with VUS. 
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Introduction 
Constitutional mismatch repair deficiency (CMMRD) caused by biallelic germline mutations in one of the 
four mismatch repair (MMR) genes confers a high risk for a broad spectrum of malignancies primarily including 
haematological malignancies, brain tumours and tumours of the Lynch syndrome (LS) spectrum. Typically, 
patients develop tumours in the first two decades of life and survivors of the primary malignancy are at high 
risk to develop a second cancer.
1
 Therefore, timely diagnosis of CMMRD is important for appropriate 
anticancer treatment
2,3,4,5
, surveillance and genetic counselling of parents regarding the recurrence risk in 
siblings as well as their own risk for LS-associated tumours. About two-thirds of CMMRD patients present with 
pigmentary alterations, most frequently café-au-lait macules (CALM) reminiscent of neurofibromatosis type 1 
(NF1)
2
, but also a variety of other unspecific pigmentation anomalies. Here, we report on a child with 
desmoplastic medulloblastoma (DMB) and peculiar skin pigmentation who meets the criteria for CMMRD 
testing.
1
 Whole exome sequencing (WES) revealed homozygous variants of uncertain significance (VUS) in 
MSH2 and MSH6. The diagnostic strategy allowing us to assign the clinical significance of these variants and 
finally to confirm CMMRD in the patient is presented. 
 
Results 
Case report 
The 13 months old girl suffering from vomiting for several weeks presented with ataxia, convergent 
strabism and developmental regression at hospitalization. Magnet resonance imaging of the brain showed 
massive hydrocephalus caused by a large infratentorial tumour (49x41x85 mm) with both solid and cystic parts 
(Figure 1D). Pathologic analysis of the resected tumour revealed desmoplastic medulloblastoma  with a 
balanced c-Myc and n-Myc status and ß-Catenin negativity. Metastases to the cerebral fluid or spinal cord were 
excluded. According to the HIT (Hirn-Tumor) guidance protocol, treatment with vincristine, cyclophosphamide, 
high-dose methotrexate, carboplatin and etoposide and intraventricular methotrexate was initiated and fairly 
well tolerated under supportive care. Radiotherapy was omitted due to the patient’s age. One year after 
diagnosis, the child is well and in complete remission. 
The patient had a very peculiar skin phenotype with a heterogeneous spectrum of pigmentary alterations 
including CALM and inguinal freckling reminiscent of NF1 as well as other hyper- and hypo-pigmented skin 
patches, atypical dermal melanocytosis/Mongolian spots and naevus-like spots (Figure 1A-B). Neither the 
 4 
healthy three-year-old sister nor the parents showed these alterations of skin pigmentation. The parents 
having both Roma background reported non-consanguinity, a pregnancy with a third child who died in utero 
for unknown reasons and a family history without cancer diagnosis in the three preceding generations (Figure 
1C).  
 
Identification of homozygous variants in MSH2 and MSH6 
The family was included in our prospective study ´Germline predisposition in children with cancer´. 
According to the study protocol, a trio-based WES analysis, including patient and both parents, was performed. 
Analysis of the WES data for causative variants in the MMR genes revealed a MSH2 missense variant 
(c.274C>G, p.(Leu92Val)) and a MSH6 3-bp deletion (del) (c.2426_2428delTAG, p.(Val809del)) both present in a 
homozygous state in the patient and heterozygous in both parents (Figure 2A).  
The ExAC-database lists the MSH2 variant with an overall minor allele frequency of G=0.00007. This 
variant located in the functionally relevant N-terminal MutS-like protein domain (Figure 2B) affects a highly 
conserved amino-acid and is predicted to be deleterious by several programs (Polyphen, SIFT, MutationTaster). 
The InSiGHT group database lists this MSH2 variant once with unknown pathogenicity (InSiGHT class 3). 
No data on the frequency in unselected individuals is available for the 3-bp del in MSH6. It is predicted to 
lead to loss of a valine (Val) in a moderately conserved region of the core domain of MSH6. In the InSiGHT 
database, this variant (2 entries) was classified as variant with unknown pathogenicity (InSiGHT class 3). 
Since, both variants were classified as VUS, neither of them could unequivocally confirm the diagnosis of 
CMMRD. Therefore, we performed additional tests in order to unravel whether the clinical phenotype of the 
child is caused by CMMRD and to render indications whether homozygosity of one or both of the VUS is 
disease causing. 
 
Diagnostic workup  
Many inactivating MSH2 missense variants lead at least to expression loss of the heterodimerisation 
partner MSH6. Therefore, we performed immunohistochemical (IHC) staining on the tumour tissue, which 
showed nuclear expression of all MMR proteins in neoplastic and non-neoplastic cells (Supplement Figure 1). 
gMSI testing performed according to the protocol developed by Ingham et al.
3
 did not reveal increased gMSI 
ratios in the patient’s lymphocytes and, hence, could not confirm CMMRD in the child.  Therefore, we next 
 5 
performed methylation tolerance and ex vivo microsatellite instability (evMSI) assays using a lymphoblastoid 
cell line (LCL) of the patient (Supplementary Material and Methods). These cells displayed a methylation-
tolerance phenotype characteristic of MMR-deficient cells (Figure 3A). Furthermore, the cell line from the 
patient achieved the evMSI phenotype as demonstrated by a 1bp-del in the NR27 microsatellite in the LCL in 
comparison to peripheral blood lymphocytes (Figure 3B). Taken together, both assays clearly confirm CMMRD 
in the patient. 
 
Discussion 
Diagnosing CMMRD has important implications for the management of paediatric cancer patients and 
their families. Therefore, coming to a definite diagnosis in a suspected patient is of utmost importance. In the 
era of large-scale sequencing the major challenge is correct classification of variants that affect functions or are 
being neutral. This case illustrates an effective diagnostic strategy to definitely confirm (or refute) CMMRD in 
patients in whom only MMR gene VUS are identified. 
 IHC staining of the MMR proteins and analysis of MSI are the preferred diagnostic methods to 
substantiate suspected CMMRD. However, due to the non-truncating nature of the VUS identified in MSH2 and 
MSH6, which is compatible with expression of a non-functional protein, IHC was not informative in our patient. 
This limitation of IHC has already been shown in other CMMRD patients.
4-6
 It is known that standard MSI 
testing developed for LS-associated tumours often fails to show MSI in brain tumours of CMMRD patients.
7
 
Therefore, we performed gMSI testing. This simple and fast assay detects altered dinucleotide-microsatellite 
alleles present at low level in non-neoplastic cells of individuals with CMMRD due to biallelic PMS2 or MLH1 
mutations. CMMRD due to bi-allelic MSH2 mutations is rare and data are therefore limited, but all cases of 
MSH2-associated CMMRD analysed so far also showed increased gMSI ratios.
3,4
 However, since the assay relies 
on the analysis of dinucleotide microsatellite markers, it is insensitive towards MSH6-associated CMMRD.
3
 
Hence, a negative gMSI result, as observed in our patient, is compatible with a constitutive MSH6 defect, but  
speaks against a defect in PMS2, MLH1 or MSH2. Another approach is based on the evaluation of MSI using 
mononucleotide markers and methylation tolerance – another functional characteristic of MMR-deficient cells 
-, in immortalized lymphoblastoid cells (i.e. ex vivo) of suspected patients.
4
 This method demonstrated 
unequivocal results in a case-control study, i.e. abnormal results for both assays were found in all CMMRD 
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patients, whereas normal results for both assays were found in the control cohort.
4
 This assay could finally 
confirm CMMRD also in our patient. 
The preserved expression of MSH2 and MSH6 and, in particular, the negative gMSI result speaks against 
an inactivation of MSH2 in the patient rendering the MSH2 variant p.(Leu92Val) unlikely the disease causing 
variant. However, these results are compatible with MSH6-associated CMMRD and, consequently, a 
deleterious effect of the MSH6 variant p.(Val809del). Hence, it is possible that the MSH2 variant is a rare 
benign variant that happens to be genetically linked to the disease causing mutation in MSH6 (distance 
between the two variants is ~39kb). This notion is corroborated by data from the UMD database, which also 
reports this MSH2 variant as “likely neutral” and together with a different clearly disease-causing MSH6 
mutation in a patient with LS. Ultimately however, functional studies would be needed to come to a final 
conclusion which of the two variants contributed to which extend to the clinical phenotype of the patient. 
Upon confirming CMMRD, our patient was integrated into a cancer surveillance program as proposed by 
the European consortium `C4CMMRD`, the international biallelic MMR deficiency consortium and the 
consensus statement of the American Association for Cancer Research.
8,9
 According to the InSiGHT-database 
the MSH6 variant was also found in patients tested for LS. We therefore assume that this variant increases the 
risk for LS-associated tumours in adult heterozygous carriers and strongly recommended that the parents are 
enrolled in a LS surveillance protocol even in absence of LS-associated tumours in their family history. The 
sister who did not show pigmentation alterations or any other signs of CMMRD was not tested for the MSH6 
variant. 
A very particular skin pigmentation phenotype was crucial for suspecting CMMRD in our patient. The girl 
not only has a large number of hyper- and hypopigmented skin areas, which are frequently reported in CMMRD 
patients, but also several Mongolian spots. With this very heterogeneous skin pigmentation phenotype she 
resembles a recently published CMMRD patient with atypical dermal melanocytosis
10
 and a patient published 
by Scott et al.
11
 These patients indicate that also multiple Mongolian spots may belong to the CMMRD-
associated skin features.  
In conclusion, our case illustrates that WES may be a valid and rapid method to confirm the diagnosis. 
However, paediatric oncologists and molecular geneticists should be prepared that the interpretation of 
sequencing data may be challenging and require thorough functional analysis to come to a valid conclusion. 
 
 7 
Informed consent 
The study was approved by the local ethics committee and written informed consent was obtained from the 
parents.  
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Titles and legends to figures 
Figure 1. A-B Variegated skin pattern with CAL spots, hypo-pigmented areas, and Mongolian and 
naevus-like spots. C Pedigree of the family; circles, females; squares, males; quarter symbol, 
heterozygous variants; half symbol, homozygous variant; black symbol, MSH2 variant; red symbol, 
MSH6 variant. D Cerebellar medulloblastoma with solid and cystic parts, T2 weighed axial. 
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Figure 2. A WES reveals a homozygous missense variant in MSH2 (c.274C>G, p.Leu92Val) and a 3-bp deletion in 
MSH6 (c.2426_2428delTAG, p.Val809del) in DNA extracted from peripheral blood of the patient. Both variants 
are heterozygous in the parents. B The MSH2 variant is located in the MutS_I protein domain and the MSH6 
variant is located in the MutS_III protein domain. C Sanger sequencing confirmed homozygosity of the two 
variants in the patient. Both variants are present in a heterozygous state in the parents. 
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Figure 3. A The lymphoblastoid cell line from the patient displayed methylation tolerance. Survival (%) of 
immortalized lymphoid cells derived from the patient (dark circles) and from an MMR wild-type control (open 
squares) after two (full lines) or three (dotted lines) rounds of MNNG treatment. B Immortalized lymphoid cells 
from the patient displayed ex vivo microsatellite instability. Electrophoretograms of fluorescent amplification 
products for NR21, NR27, and BAT26 microsatellites, respectively. The length of the predominant allele (in base 
pairs) and the fluorescence intensity are indicated in the box below each profile. A 1bp deletion (red arrow) 
occurred at the NR27 locus in the lymphoblastoid cell line (LCL) derived from the patient compared with the 
respective peripheral blood lymphocytes (PBLs). 
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